Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
09:00am, Wednesday, 01'st May 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operatin
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 30'th Apr 2024
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Announces Life Science Group Management Changes
08:30am, Friday, 26'th Apr 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James
New Strong Sell Stocks for April 19th
05:26am, Friday, 19'th Apr 2024
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
11:06am, Thursday, 18'th Apr 2024
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
09:00am, Thursday, 18'th Apr 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
12:01pm, Tuesday, 16'th Apr 2024
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
05:44pm, Thursday, 11'th Apr 2024
– Bio-Rad expects to make equity investment in support of deal – Agreement provides for global exclusivity in transplant monitoring commercialization – Bio-Rad granted su
Bio-Rad's Chief Operating Officer Andrew Last to Retire
04:15pm, Wednesday, 10'th Apr 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, E
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
08:30am, Wednesday, 20'th Mar 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju
Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition
09:31am, Tuesday, 12'th Mar 2024
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
04:30pm, Thursday, 22'nd Feb 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's mana
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
09:15am, Tuesday, 20'th Feb 2024
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m
Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down
10:25am, Friday, 16'th Feb 2024
Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.
Bio-Rad Laboratories (BIO) Surpasses Q4 Earnings Estimates
06:31pm, Thursday, 15'th Feb 2024
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.10 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.31 per share a year ago.
